BREAST CANCER

According to findings recently published online in the<em> Journal of Clinical Oncology, </em>12<em>&nbsp;</em>weeks of neoadjuvant T-DM1 (ado-trastuzumab emtansine; Kadcyla) with or without endocrine therapy induced superior pathologic complete response (pCR) compared with trastuzumab (Herceptin) plus endocrine therapy in patients with HER2-positive/HR-positive early breast cancer.

Adding pertuzumab to standard postoperative trastuzumab therapy in patients with HER2-positive early breast cancer improved the rate of recurrence overall, but had a greater benefit for individuals with higher-risk disease, according to results from the phase III APHINITY trial.

Sacituzumab govitecan (IMMU-132) was well tolerated and demonstrated early and durable responses in heavily pretreated patients with metastatic triple-negative breast cancer (mTNBC), according to the results of a recent phase I/II study published in the <em>Journal of Clinical Oncology</em>.<br /> &nbsp;

Lisa Carey, MD, discusses&nbsp;strategies that can be used to de-escalate treatment in patients with triple-negative breast cancer and the steps toward developing further strategies in this area.

A look back at all the FDA news that occurred in July.

During the 2017 ESMO Congress, to be held September 8-12 in Madrid, Spain, the European Society for Medical Oncology (ESMO) will award 4 oncologists with its distinguished annual awards:

The use of fulvestrant (Faslodex) to treat estrogen receptor (ER)-positive, locally-advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy has been approved by the European Commission (EC).

The challenge of precision medicine in metastatic breast cancer is to develop well-tolerated therapies based on key actionable, accessible, and validated biomarkers, said Francisco J. Esteva, MD, PhD, during an explanation of the current understanding of the molecular landscape of metastatic breast cancer at the <em>16th Annual </em>International Congress on the Future of Breast Cancer East.

In the neoadjuvant and adjuvant settings of treating patients with HER2-positive breast cancer, trastuzumab (Herceptin) remains a standard of care. The question has become whether combination regimens with additional HER2-directed therapies or alternative therapies could improve responses in this patient population without added toxicities, according to Sara M. Tolaney, MD, MPH.

Checkpoint inhibitors against PD-1 and PD-L1 have demonstrated promising efficacy as monotherapies and in combination with chemotherapy for patients with triple-negative breast cancer, with phase III data on the horizon

Mark Pegram, MD, shares some of the most recent developments in the HER2-positive metastatic breast cancer space, the research currently ongoing, and why it is such an exciting time for the field.

Joyce O&rsquo;Shaughnessy, MD, provides an update on existing research in metastatic triple-negative breast cancer, and novel agents on the horizon.

In an interview with <em>Targeted Oncology,&nbsp;</em>Arti Hurria, MD,&nbsp;shares the treatment considerations she makes when treating older patients with breast cancer, the unique challenges that come with treating this patient population, and the exciting future she envisions for this space.

MYL-1401O, the trastuzumab (Herceptin) biosimilar manufactured by Mylan Pharmaceuticals, has been recommended for approval by the FDA&#39;s&nbsp;Oncologic Drugs Advisory Committee (ODAC) in a 16-0 vote.

Hope S. Rugo, MD,&nbsp;professor of medicine and director of the Breast Oncology Clinical Trials Program at the UCSF Helen Diller Family Comprehensive Cancer Center, discusses extended adjuvant endocrine therapy for patients with HR+ breast cancer.

Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses the utility of molecular signatures in managing early-stage breast cancer.

Neratinib (Nerlynx) has been approved by the FDA for the extended adjuvant treatment of patients with early stage HER2-positive breast cancer following postoperative treatment with trastuzumab (Herceptin).&nbsp;

A new drug application (NDA) for abemaciclib has been granted a priority review by the FDA as a treatment for patients with advanced hormone receptor (HR)&shy;&shy;&ndash;positive, HER2-negative breast cancer.

Rita Nanda, MD, assistant professor of Medicine, assistant director, Breast Medical Oncology, discusses results from I-SPY 2, which explored pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer.&nbsp;

The Breast Cancer Weight Loss Study is looking to identify the relationship between obesity and recurrence in breast cancer through a phone-based weight loss intervention program.

Abemaciclib penetrated brain metastases and had antitumor activity in patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer, preliminary evidence suggests.

Gunter von Minckwitz, MD, PhD, president of the German Breast Group in Neu-Isenburg, Germany, discusses results from the large phase III APHINITY trial, which explored the addition of pertuzumab (Perjeta) to adjuvant trastuzumab and chemotherapy for patients with HER2-positive early breast cancer.

Rachel A. Freedman, MD, MPH, discusses a phase II trial of neratinib plus capecitabine for patients with HER2-positive breast cancer brain metastases.

In patients with heavily pretreated metastatic triple-negative breast cancer, pembrolizumab showed durable antitumor activity, according to findings from cohort A of the phase II KEYNOTE-086 trial.

Harold J. Burstein, MD, PhD, institute physician, Dana-Farber Cancer Institute,&nbsp;associate professor of Medicine, Harvard Medical School, discusses a survey of how clinicians use genomic assays to assist in decision-making regarding the use of neoadjuvant and adjuvant chemotherapy for patients with ER-positive/HER2-negative early breast cancer.

Alexandra S. Zimmer, MD, staff clinician, Women&#39;s Malignancies Branch, National Cancer Institute Center for Cancer Research, discusses the promising data seen thus far with olaparib (Lynparza) for the treatment of HER2-negative breast cancer.

Psychological intervention can substantially lower fear of cancer recurrence (FCR) in survivors, improving their quality of life, anxiety, and cancer-specific distress.

Ribociclib has been recommended for approval by the Committee for Medicinal Products for Human Use, a part of the European Medicines Agency, for use in combination with an aromatase inhibitor as a first-line treatment for postmenopausal women with HR-positive /HER2-negative locally advanced or metastatic breast cancer.<br /> &nbsp;

Targeted therapy through the use of antibody&ndash;drug conjugates holds great promise for the treatment of many malignancies, in particular, breast cancer.

Sylvia Adams, MD, associate professor, Department of Medicine, NYU Langone Medical Center, discusses phase II results from cohort A of the KEYNOTE-086 trial, which explored pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer.